FCP
TIL icon

Fidelis Capital Partners’s Instil Bio TIL Stock Holding History

Fidelis Capital Partners’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-564
Closed -$4.83K – 336
2023
Q3 		$4.83K Sell
564
-99
-15% -$997 ﹤0.01% 271
2023
Q2 		$7.31K Buy
+663
New +$8.1K ﹤0.01% 273

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelis Capital Partners's TIL Position: Q4 2023 in Review

Fidelis Capital Partners sold out of Instil Bio (TIL) in Q4 2023, closing a stake of 564 shares — an estimated $4.83K sold.

Fidelis Capital Partners first reported a position in TIL in Q2 2023 and held it in 2 quarters. The position peaked at $7.31K in Q2 2023. 30 funds tracked by Wall St. Rank hold TIL as of Q4 2023.

  • Fidelis Capital Partners reported no remaining Instil Bio position as of Q4 2023 after selling out during the quarter.
  • Fidelis Capital Partners sold 564 Instil Bio shares in Q4 2023, an estimated $4.83K.
  • Fidelis Capital Partners first reported a position in Instil Bio in Q2 2023 and held it in 2 quarters.
  • Fidelis Capital Partners's Instil Bio position peaked at $7.31K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Instil Bio as of Q4 2023.

Based on Fidelis Capital Partners's 13F filing for Q4 2023, filed 31 Jan 2024.